כנסים 26.03.2018

סיקור כנס אונקולוגיה אורולוגית

15-17 במרץ 2018 | מלון אוריינט, ירושלים | בחסות טבע ומדיסון

דברי פתיחה - ד"ר וילי מרמלשטיין

Surgical Considerations in the Treatment of Residual Disease When and to Whom? Prof. Jack Baniel (Bellinson MC)

Debate: House believes - Surgery is the best Treatment option in the High-Risk Prostate Cancer. Prof. Ilan Leybovich (Meir MC)

Decision making in the treatment paradigm in Advanced Lines of mRCC. The Expert Insight Prof. Manuela Shmidinger (Sponsored by Medison)

Debate: House believes - Radiation Therapy combined with Hormonal Treatment is the Best Treatment Option in High-Risk Prostate Cancer. Prof. Eliahu Gez (Tzfat MC)

Debate: HSPC. House believes - Abiraterone Acetate Combined with ADT is the Best First Line Treatment Option. Dr. Steve Frank.(Hadassa MC)

Debate: HSPC. House believes - Docetaxel Combined with ADT is the Best First Line Treatment Option. Dr. Raya Leibovich (Sheba MC)

Debate – Management of Stage IIA-IIB Seminoma. House believes - Radiation Therapy is Preferred Option. Dr. Marc Wygoda (Hadassa MC)

Value and Timing of High-dose chemotherapy with Autologous Stem Cell Rescue in the Failure of Previous Treatment. Dr. Daniel Goldshtein (Bellinson MC)

Invited Lecture – Navigation in Multiple Genomic Tests – What the Oncologist Should Know. Dr. Gilad Vainer, (Institute of Pathology, Sourasky MC)

Debate - Management of Stage IIA-IIB Seminoma. House believes - Chemotherapy is Preferred Option. Dr. Avivit Noiman (Rambam MC)

Updates in the management of Castrate – Resistant Prostate Cancer (CRPC). Dr. Avivit Peer (Rambam MC) (Sponsored by Astellas)

Challenging Case Presentations – Prof. Avishay Sella (Asaf Harofe) and Dr. Michal Sarfaty (Bellinson MC)

First-Line Chemotherapy for High-Risk GCT: Do We Need Dose Intensification? Prof. Avishay Sella (Asaf Harofe MC)

Long-term Health Outcomes of Germ Cell Tumor Survivors. Dr. Willy Mermelshtein (Soroka MC)

Results of POUT Study – Is It a New Standard of Care in Upper-Tract Urothelial Carcinoma? Dr. Noa Shani Shrem (Soroka MC)

Current Dilemmas in the Choice of First Line Treatment in mUC. Dr. Michal Sarfaty (Bellinson MC) (Sponsored by Roche)

mUC & Predictors of Response to IO agents. Dr. David Sarid (Sourasky MC) (Sponsored By A-Z)

נושאים קשורים:  כנסים
מאמרים נוספים שיעניינו אותך
תגובות
 
האחריות הבלעדית לתוכנן של תגובות שיפורסמו על ידי משתמשי האתר, תחול על המפרסם ועליו בלבד. על המגיבים להימנע מלכלול בתגובות תוכן פוגעני או כל תוכן אחר, שיש בו משום פגיעה או הפרת זכויות של גורם כלשהו